PainChek General Discussion, page-11162

Yes, maybe more, here's my more detailed opinion.

https://docs.google.com/spreadsheets/d/1-RfT2izeKSqHLt9jYotj0_nt_mAQt8ZYEf59lkUyojE/edit?usp=sharing

I've posted it a few times now. Ultimately depends if you think the products will be a success. Enterprise dementia product is already showing early signs of success here in Australia, and is kicking off in NZ and the UK. I think rollout may accelerate, as they've likely gone through any teething issues here in the initial stages. I also think dementia direct to carer will be successful. The children's app, well if that can grab even a small %age of the target market PCK will be a behemoth, I personally think that's wishful thinking but not an impossibility.

PE, depends on many factors whether or not PE 20 would be reasonable. For a stock showing consistent growth, and a good revenue model, PE 20 is decent buying IMO.
https://www.investopedia.com/terms/p/price-earningsratio.asp